Additionally, the 36-month beta value for AUTL is 1.97. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for AUTL is 157.78M and currently, short sellers hold a 2.64% ratio of that float. The average trading volume of AUTL on April 18, 2024 was 1.55M shares.
AUTL) stock’s latest price update
The stock price of Autolus Therapeutics plc ADR (NASDAQ: AUTL) has surged by 3.31 when compared to previous closing price of 4.84, but the company has seen a -6.19% decline in its stock price over the last five trading sessions. GlobeNewsWire reported 2024-02-29 that LONDON, Feb. 29, 2024 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that it will release its fourth quarter and full year 2023 results and operational highlights on Thursday March 14, 2024. Management will host a conference call and webcast at 8:30 am EDT/12:30 pm GMT to discuss the company’s financial results and provide a general business update.
AUTL’s Market Performance
AUTL’s stock has fallen by -6.19% in the past week, with a monthly drop of -19.35% and a quarterly drop of -20.89%. The volatility ratio for the week is 5.70% while the volatility levels for the last 30 days are 5.91% for Autolus Therapeutics plc ADR The simple moving average for the past 20 days is -11.50% for AUTL’s stock, with a 15.07% simple moving average for the past 200 days.
Analysts’ Opinion of AUTL
Many brokerage firms have already submitted their reports for AUTL stocks, with Deutsche Bank repeating the rating for AUTL by listing it as a “Buy.” The predicted price for AUTL in the upcoming period, according to Deutsche Bank is $10 based on the research report published on November 09, 2023 of the previous year 2023.
Wells Fargo, on the other hand, stated in their research note that they expect to see AUTL reach a price target of $8. The rating they have provided for AUTL stocks is “Overweight” according to the report published on March 27th, 2023.
Bryan Garnier gave a rating of “Buy” to AUTL, setting the target price at $5 in the report published on March 17th of the previous year.
AUTL Trading at -15.89% from the 50-Day Moving Average
After a stumble in the market that brought AUTL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -32.89% of loss for the given period.
Volatility was left at 5.91%, however, over the last 30 days, the volatility rate increased by 5.70%, as shares sank -23.28% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -21.61% lower at present.
During the last 5 trading sessions, AUTL fell by -5.72%, which changed the moving average for the period of 200-days by +97.83% in comparison to the 20-day moving average, which settled at $5.57. In addition, Autolus Therapeutics plc ADR saw -22.36% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for AUTL
Current profitability levels for the company are sitting at:
- -48.43 for the present operating margin
- -0.6 for the gross margin
The net margin for Autolus Therapeutics plc ADR stands at -60.0. The total capital return value is set at -0.51. Equity return is now at value -101.61, with -48.14 for asset returns.
Based on Autolus Therapeutics plc ADR (AUTL), the company’s capital structure generated 0.32 points at debt to capital in total, while cash flow to debt ratio is standing at -2.75. The debt to equity ratio resting at 0.48. The interest coverage ratio of the stock is -3.73.
Currently, EBITDA for the company is -188.46 million with net debt to EBITDA at 1.18. When we switch over and look at the enterprise to sales, we see a ratio of 197.17. The receivables turnover for the company is 0.14for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.11.
Conclusion
In conclusion, Autolus Therapeutics plc ADR (AUTL) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
